Fast Five Quiz: Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, MD; Winston W. Tan, MD, FACP


August 16, 2023

Multiple myeloma is a plasma cell cancer characterized by the proliferation of monoclonal plasma cells in bone marrow, leading to an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. The condition comprises an estimated 15% of hematologic cancer types. The incidence rate of multiple myeloma has increased by 126% worldwide since 1990. Unlike other cancer types that metastasize to the bone, up to 80% of patients with newly diagnosed multiple myeloma present with osteolytic lesions. Other signs of multiple myeloma include anemia, hypercalcemia, and renal disfunction. Owing to the nature of the disease, most patients with multiple myeloma will experience relapse, with subsequent lines of therapy selected on the basis of prior treatment, patient condition, and patient preference.

How would you approach the diagnosis, monitoring, and management of relapsed/refractory multiple myeloma? Check your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.